[1] BORLAUG B A, SHARMA K, SHAH S J, et al. Heart failure with preserved ejection fraction: JACC scientific statement[J]. J Am Coll Cardiol, 2023, 81(18): 1810-1834. [2] KHAN M S, SHAHID I, BENNIS A, et al. Global epidemiology of heart failure[J]. Nat Rev Cardiol, 2024, 21(10): 717-734. [3] HAMO C E, DEJONG C, HARTSHORNE-EVANS N, et al. Heart failure with preserved ejection fraction[J]. Nat Rev Dis Primers, 2024, 10: 55. [4] MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2022, 24(1):4-131. [5] WANG M, LI D, LI J, et al. Professional competencies in geriatric nursing for geriatric nurses: a latent profile analysis[J]. BMC Nurs, 2024, 23(1): 512. [6] TEIN J Y, COXE S, CHAM H. Statistical power to detect the correct number of classes in latent profile analysis[J]. Struct Equ Modeling, 2013, 20(4): 640-657. [7] 射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J]. 中国循环杂志, 2023, 38(4): 375-393. [8] MATSUSHITA K, HARADA K, KOHNO T, et al. Comparison of clinical characteristics and prognostic factors in patients with heart failure with preserved ejection fraction with and without renal dysfunction[J]. Minerva Cardiol Angiol, 2024, 72(6): 615-624. [9] CHEN M, LI W, RAN Q. Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension[J]. BMC Cardiovasc Disord, 2024, 24(1): 742. [10] VU H H, MOELLMER S A, MCCARTY O J T, et al. New mechanisms and therapeutic approaches to regulate vascular permeability in systemic inflammation[J]. Curr Opin Hematol, 2025, 32(3): 130-137. [11] BAUDRY N, CAMPEANU A, AUSSEL C, et al. IL-1β primed mesenchymal stromal cells moderate hemorrhagic shock-induced vascular permeability[J]. J Transl Med, 2024, 22(1): 1143. [12] RICCI F, SARAULLO S, BOCCATONDA A, et al. Early prescription of SGLT2i for acute patient care: from current evidence to future directions[J]. Curr Probl Cardiol, 2025, 50(8): 103081. [13] BERGER M, MÄRZ W, NIESSNER A, et al. IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction[J]. ESC Heart Fail, 2024, 11(6): 3607-3615. [14] MELENDO-VIU M, RAPOSEIRAS-ROUBÍN S, ABU-ASSI E, et al. Heart failure in older patients with atrial fibrillation: incidence and risk factors[J]. Rev Esp Cardiol: Engl Ed, 2024, 77(1): 19-26. [15] RAKISHEVA A, SOLOVEVA A, SHCHENDRYGINA A, et al. Heart failure with preserved ejection fraction and frailty:from young to superaged coexisting HFpEF and frailty[J]. Int J Heart Fail, 2024, 6(3): 93-106. [16] VERMA S, BUTLER J, BORLAUG B A, et al. Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: step-HFpEF program[J]. J Am Coll Cardiol, 2024, 84(17): 1603-1614. |